Booster Shots More Effective During Omicron Emergence Period
Booster doses seem effective for the severe acute respiratory syndrome coronavirus 2 omicron variant.
Booster doses seem effective for the severe acute respiratory syndrome coronavirus 2 omicron variant.
Researchers conducted a study to assess whether nonpharmaceutical interventions effectively prevent COVID-19 transmission following high-risk exposures.
Pfizer Inc. announced that it has launched a trial that will compare its existing COVID-19 vaccine against a new version tailored to beat back the highly contagious omicron variant.
Researchers sought to assess outcomes among patients in South Africa who were hospitalized with COVID-19 infection during the Omicron wave compared with previous waves.
Researchers conducted a study to determine the relationship between immune dysfunction and the risk for COVID-19 breakthrough infection following vaccination.
The risk for hospitalization for COVID-19 among older Americans is far higher for those who are unvaccinated than for those who are fully vaccinated and have had a booster shot, new government data show.
Barney Stern, MD, and Andrew Russman, DO, share how the COVID-19 pandemic has changed neurology practice, including patient access to care, staffing shortages, and increased burnout.
Vaccine effectiveness against symptomatic COVID-19 decreases by 20 weeks after the second dose of BNT162b2 or CHAdOx1-S, but limited waning is seen against COVID-19-related hospitalization and death.
Researchers sought to assess whether COVID-19 infection developed despite of vaccination among patients with multiple sclerosis or neuromyelitis optica spectrum disorder, using a French database of these patient populations.
Two doses of the BNT162b2 vaccine are highly effective against COVID-19-related hospitalization and critical disease in adolescents aged 12 to 18 years.